Timothy G. Youngquist 2020 Irrevocable Trust Boosts Stake in Relay Therapeutics, Inc. $RLAY

Key Points

• Timothy G. Youngquist 2020 Irrevocable Trust increased its Relay Therapeutics stake by 60.6% in the second quarter to 801,464 shares, worth approximately $15 million. Institutional investors collectively own 96.98% of the company.
• Insiders have been net sellers, with executives selling 409,639 shares worth about $7.2 million over the past 90 days; the CEO and another insider recently reduced their holdings.
• Analyst sentiment remains broadly positive, with a consensus “Moderate Buy” rating and an average price target of $25.83, despite Relay missing quarterly EPS and revenue estimates.

Timothy G. Youngquist 2020 Irrevocable Trust raised its stake in Relay Therapeutics, Inc. (NASDAQ:RLAY - Free Report) by 60.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 801,464 shares of the company's stock after acquiring an additional 302,406 shares during the period. Relay Therapeutics makes up about 2.9% of Timothy G. Youngquist 2020 Irrevocable Trust's portfolio, making the stock its 5th biggest holding. Timothy G. Youngquist 2020 Irrevocable Trust owned approximately 0.42% of Relay Therapeutics worth $14,995,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently modified their holdings of the company. California State Teachers Retirement System raised its stake in Relay Therapeutics by 47.9% in the first quarter. California State Teachers Retirement System now owns 174,099 shares of the company's stock valued at $1,732,000 after purchasing an additional 56,422 shares in the last quarter. Alphabet Inc. bought a new stake in Relay Therapeutics during the second quarter worth about $26,382,000. Persistent Asset Partners Ltd acquired a new stake in Relay Therapeutics during the second quarter worth about $1,323,000. Sanctuary Advisors LLC acquired a new stake in Relay Therapeutics during the fourth quarter worth about $1,203,000. Finally, Affinity Asset Advisors LLC bought a new position in Relay Therapeutics in the 1st quarter valued at about $3,980,000. 96.98% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Relay Therapeutics

In related news, insider Peter Rahmer sold 50,000 shares of Relay Therapeutics stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $19.09, for a total transaction of $954,500.00. Following the sale, the insider directly owned 225,857 shares in the company, valued at $4,311,610.13. This trade represents a 18.13% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Sanjiv Patel sold 48,199 shares of the business's stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $19.58, for a total transaction of $943,736.42. Following the sale, the chief executive officer directly owned 615,898 shares in the company, valued at $12,059,282.84. The trade was a 7.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 409,639 shares of company stock worth $7,233,399 in the last 90 days. Corporate insiders own 5.04% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on RLAY shares. Zacks Research downgraded shares of Relay Therapeutics from a "hold" rating to a "strong sell" rating in a report on Wednesday, July 22nd. JPMorgan Chase & Co. lifted their price objective on shares of Relay Therapeutics from $28.00 to $31.00 and gave the company an "overweight" rating in a research note on Friday, August 14th. UBS Group set a $26.00 target price on Relay Therapeutics in a research note on Tuesday, May 19th. HC Wainwright raised their target price on Relay Therapeutics from $25.00 to $28.00 and gave the company a "buy" rating in a report on Tuesday, May 26th. Finally, Citizens Jmp boosted their price target on Relay Therapeutics from $21.00 to $26.00 and gave the stock a "market outperform" rating in a report on Monday, August 10th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and two have given a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $25.83.

Relay Therapeutics Stock Down 0.3%

NASDAQ RLAY opened at $20.61 on Wednesday. The company has a market cap of $4.52 billion, a price-to-earnings ratio of -13.13 and a beta of 1.69. Relay Therapeutics, Inc. has a twelve month low of $3.31 and a twelve month high of $20.99. The business's fifty day moving average is $18.51 and its 200 day moving average is $14.14.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.39) by ($0.02). The business had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.96 million. On average, research analysts anticipate that Relay Therapeutics, Inc. will post -1.58 earnings per share for the current fiscal year.

About Relay Therapeutics

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source